FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1065-1066 October 4, 2001 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: A prior report from an Eastern Cooperative Oncology Group trial of adjuvant therapy (EST 2284), one of the trials that provided samples for the study by Watanabe et al. (April 19 issue),¹ showed that there is a statistically significant association between low-level amplification of the c-myc gene and improved responses to fluorouracil.² Subsequently, it was also shown that both wild-type p53 and very high levels of c-myc are required for the induction of apoptosis of colon-cancer cells by fluorouracil in vitro.³ Moreover, only patients whose tumors had amplified c-myc and wild-type p53 had good . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.